Fox Run Management’s MaxCyte MXCT Stock Holding History

Fox Run Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,510	Closed	-$62K	–	885
2023 Q2	$62K	Buy	+13,510	New	+$62.1K	0.02%	644

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's MXCT Position: Q3 2023 in Review

Fox Run Management sold out of MaxCyte (MXCT) in Q3 2023, closing a stake of 13,510 shares — an estimated $62K sold.

Fox Run Management first reported a position in MXCT in Q2 2023 and held it in 1 quarter. The position peaked at $62K in Q2 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q3 2023.

Fox Run Management reported no remaining MaxCyte position as of Q3 2023 after selling out during the quarter.
Fox Run Management sold 13,510 MaxCyte shares in Q3 2023, an estimated $62K.
Fox Run Management first reported a position in MaxCyte in Q2 2023 and held it in 1 quarter.
Fox Run Management's MaxCyte position peaked at $62K in Q2 2023.
120 funds tracked by Wall St. Rank held MaxCyte as of Q3 2023.

Based on Fox Run Management's 13F filing for Q3 2023, filed 7 Nov 2023.